For Media: UK Press Releases

Bayer’s Asundexian Met Primary Efficacy and Safety Endpoints in Landmark Phase III OCEANIC-STROKE Study in Secondary Stroke Prevention

Chemicals Regulation Directorate lifts restriction for Bayer’s Iblon® fungicide and adds barley to approved crops

Bayer receives authorisation in GB for Jessico® Fusion fungicide

Bayer receives MHRA authorisation for new indication of Nubeqa® (darolutamide) plus androgen deprivation therapy as a treatment option in metastatic hormone-sensitive prostate cancer

Data from Phase III OASIS-4 study to be presented at 2025 ASCO Annual Meeting

Bayer receives MHRA authorisation for...

Bayer’s investigational MRI contrast agent gadoquatrane meets primary and main secondary endpoints in Phase III studies